SAN DIEGO CA, July 24, 2017 – GenomeDx Biosciences, a leader in the field of urologic cancer genomics, announced that it has launched the Color Hereditary Cancer Test as part of its product offering to urologists. The Color Hereditary Cancer Test is performed by Color at its CLIA-certified, CAP-accredited laboratory, and analyzes 30 genes associated with increased genetic risk for most common hereditary cancers. The test is intended to help patients diagnosed with prostate cancer understand the hereditary factors of their disease and the possible implications for their family members. In addition, the Color Hereditary Cancer Test is intended to enable family members who have a relative diagnosed with hereditary prostate cancer, to determine if they are at higher risk for developing certain types of hereditary cancer in the future.
This collaboration with Color is consistent with GenomeDx’s goal to provide the best genomic and genetic solutions for patients afflicted with prostate cancer. Furthermore, GenomeDx patients taking the Color Hereditary Cancer Test will have data added to GenomeDx’s Decipher GRID research platform – aiding in research activities to discover and develop future cancer solutions.
The Color Hereditary Cancer Test is now available to physicians through GenomeDx’s commercial channel. The results will be delivered to both physicians and patients, with the opportunity to speak with one of Color’s genetic counselors to discuss test results.
Color is a health technology service that offers physician-ordered genetic testing for hereditary cancer risk. The Color [Hereditary Cancer] Test analyzes 30 genes that impact most common hereditary cancers, including prostate, breast, ovarian, colorectal, pancreatic, uterine, melanoma, and stomach cancers. To learn more about Color, follow Color on Twitter @Color or Facebook at facebook.com/Color and visit color.com.
About Decipher Cancer Classifier Tests and GRID®
GenomeDx’s Decipher prostate and bladder cancer classifier tests are commercially available genomic tests that provide a genomic assessment of tumor aggressiveness for individual patients. Decipher Biopsy is indicated for men with localized prostate cancer at diagnosis, Decipher Post-Op is indicated for men after prostate removal surgery, and Decipher Bladder is indicated for patients being considered for neoadjuvant chemotherapy prior to bladder removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups than determined by traditional diagnostic tools and to help determine which patients may be more likely to benefit from additional treatment.
The Decipher tests are derived from GenomeDx’s Decipher Genomics Resource Information Database (GRID). GRID contains the genomic profiles of thousands of tumors from patients with urological cancers, and is believed by GenomeDx to be the largest shared genomic expression database in urologic cancer as well as one of the world’s largest global RNA expression databases using cloud-based analytics. Each tumor analyzed with a Decipher test adds new data to the GRID database, which is compiled into a Decipher GRID Profile that may reveal additional biological characteristics of the tumor for ongoing research purposes. Going beyond risk stratification, Decipher and GRID make genetic information accessible for researchers to predict responses to therapy better and to guide treatment more precisely. In addition, GRID is a platform for interactive research collaboration, and may enable more rapid discovery, development, commercialization and adoption of new genomic solutions for key clinical questions in cancer treatment.
About GenomeDx Biosciences
GenomeDx is reimagining the use of genomics as a platform for mass collaboration to improve patient treatment and outcomes through its currently available genomic tests for prostate and bladder cancer as well as potential future tests. GenomeDx is headquartered in Vancouver, British Columbia, and operates a clinical laboratory in San Diego, California.
Learn more at www.GenomeDx.com